23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently exclude some drugs' option-related benefits, reducing their reimbursement chances, and making them less attractive R&D investments. 

Cook and Golec developed and tested a real options model of R&D investment that shows that excluding option-related benefits heightens drug developers' incentives to avoid high-risk (volatile) R&D investments and instead encourages them to focus on “safer” (positively skewed) investments. 

Their model and empirical results could partly explain the decline in the number of risky new molecular entities.

Read Health Economics article